Lilly puts Zepbound and Foundayo on Hims
Also in this issue: Zepbound from $299, Foundayo from $149 on Hims
Forwarded this? Get it weekday mornings.
Take. The biggest cash-pay telehealth funnel now carries Lilly's branded injectable and daily oral at published self-pay floors. Compound sellers no longer price only against LillyDirect. Re-check your cash-pay compare rate against those floors before you rewrite Monday's board or your intake script. Until Hims posts live SKU pages, we would put the $299 / $149 floors on the compare sheet and keep medicine separate from membership.
Eli Lilly and Hims & Hers said Friday that eligible patients prescribed on the Hims platform can get FDA-approved Zepbound and Foundayo (orforglipron) at the same self-pay prices available elsewhere, without leaving Hims. Self-pay pricing starts at $299 a month for Zepbound and $149 a month for Foundayo. The flow is consult, prescription if appropriate, then home delivery. Hims says it has never offered compounded copies of Lilly's GLP-1s and commits not to. Both releases treat rollout as forward-looking. Neither states a promo end date, a dose ladder, or whether membership sits on top of the "starts at" medicine price.
That branded floor now sits next to the low compounded all-in cards. Clinics that still pitch "branded means leave our site" lose that line.
| When | Who | Side | Status |
|---|---|---|---|
| Today after close | Hims & Hers Q3 | Earnings call 5 p.m. ET | Today |
| Friday | HHS peptide comments close | Docket HHS-OASH-2026-0496 | This week |
The Signal
Telehealth
Elysium plans six HHS peptides on its Rx arm
Elysium Health said Thursday it plans to offer BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500 through Elysium Health Rx by year-end. Access is physician-evaluated and state-dependent. The company also launched PEER, an institutional peptide research program, and plans TIME-PEP, an epigenetic study of peptide users.
The release points to HHS's interim 503A compounding enforcement-discretion policy in the Federal Register (notice published Oct. 30, docket HHS-OASH-2026-0496). Elysium states the policy is not FDA approval. It also says compounded drugs are not FDA-reviewed for safety, effectiveness or quality. Comments on that notice close Friday. A well-known longevity brand turning the six-peptide discretion into a consumer telehealth SKU before the comment deadline raises the bar on sourcing and labeling. Clinics will need a plain line for patients on "discretion, not approval."
Marketing
Good Life will comply with NAD on Tirzepatide+
After BBB National Programs' National Advertising Division recommended that Good Life Meds drop unsupported health-benefit and personalization claims for compounded "Tirzepatide+," the company said it disagrees with many aspects of the decision and "will comply with NAD's recommendations." That is self-regulation, not an FDA action or a court order.
Telehealth
Stratford remote-care firm files Chapter 11
TapestryHealth and ten affiliates filed voluntary Chapter 11 petitions Friday in Delaware under Case No. 26-11777, per Stretto. The petition estimates assets of $50 million to $100 million and liabilities of $10 million to $50 million. Bloomberg Law reports the company services about 80,000 Medicare beneficiaries at about 1,500 skilled nursing facilities and alleges CMS suspended reimbursements. An adversary proceeding against HHS leadership opened the same day. This is SNF chronic-care telehealth, not a GLP-1 clinic. It is the second telehealth-linked Delaware filing in a week after FuturHealth.
Operator Q&A
Same-day cancel: fee or fill the slot?
No federal rule settles clinic cancellation fees. That choice belongs in your contract, booking-vendor terms and card-network dispute practice.
The Price Board: cash GLP-1 prices
Semaglutide per month
3 of 82 prices shown
ODR Price Board optimized.news, checked Nov. 2-12, 2026
| Seller | Per monthAll-in median $175 | Read |
|---|---|---|
| OurView HealthSemaglutideCompoundedMedication, online consultation, shipping options | ||
Pricing varies by offer; this is our calculation from the seller's public page. | ||
| Bayan HealthSemaglutide + vitamin B6CompoundedMedication, physician consultation, free expedited shipping; labs only "if needed" | ||
Pricing varies by offer; this is our calculation from the seller's public page. | ||
| FrontCareSemaglutideCompoundedProvider review, medication, syringes/supplies, 2-day shipping | ||
Pricing varies by offer; this is our calculation from the seller's public page. | ||
Tirzepatide per month
1 of 77 prices shown
ODR Price Board optimized.news, checked Nov. 2-12, 2026
| Seller | Per monthAll-in median $239 | Read |
|---|---|---|
| PreventiveMDTirzepatideCompoundedMedication and provider review | ||
Pricing varies by offer; this is our calculation from the seller's public page. | ||
Wire
- Hims & Hers reports third-quarter results today after the close, with a call at 5 p.m. ET, per its investor site.
- CMS's CY2027 Physician Fee Schedule final rule is set to publish in the Federal Register today (public inspection 2026-22743), including BB/BC telehealth modifiers from Jan. 1.
- Comments on HHS's 503A peptide enforcement-discretion policy close Friday (docket HHS-OASH-2026-0496). Enforcement discretion is not approval.
Optimized Daily Report is business news for clinic operators. Not medical, legal, or investment advice. Company claims are the company's.